Earnings ·
Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, an 11% increase year-over-year from $20.5…
HBIOHarvard Bioscience Inc
Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, an 11% increase year-over-year from $20.5 million, and raised its full-year 2026 revenue growth guidance to 3%-5%. The company posted a net loss of ($2.9) million for the quarter compared to ($2.3) million in the prior year period, while adjusted EBITDA improved to $1.7 million from $1.5 million. Full-year adjusted gross margin is now targeted between 57% and 59%, with adjusted EBITDA growth expected between 6% and 10%. The filing notes a 1-for-10 reverse stock split effective March 13, 2026. Harvard Bioscience develops, manufactures, and sells technologies for life science applications including research, drug discovery, and preclinical testing.